An epigenetic reprogramming strategy to resensitize radioresistant prostate cancer cells

Cancer Research

Volumn 76, Issue 9, 2016, Pages 2637-2651

  Peitzsch, Claudia ^a   Cojoc, Monica ^a   Hein, Linda ^a   Kurth, Ina ^a   Mäbert, Katrin ^a   Trautmann, Franziska ^a   Klink, Barbara ^a,b   Schröck, Evelin ^a,b   Wirth, Manfred P ^a   Krause, Mechthild ^a,b,c   Stakhovsky, Eduard A ^d   Telegeev, Gennady D ^e   Novotny, Vladimir ^a   Toma, Marieta ^a   Muders, Michael ^a   Baretton, Gustavo B ^a   Frame, Fiona M ^f   Maitland, Norman J ^f   Baumann, Michael ^a,b,c   Dubrovska, Anna ^a,b,c  

^a UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^b GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

^c INSTITUTE OF ION BEAM PHYSICS AND MATERIALS RESEARCH   (Germany)

^d NATIONAL CANCER INSTITUTE   (Ukraine)

^e INSTITUTE OF MOLECULAR BIOLOGY AND GENETICS   (Ukraine)

^f UNIVERSITY OF YORK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CELL MARKER; HISTONE H3; ALDH1A2 PROTEIN, HUMAN; HISTONE; RETINAL DEHYDROGENASE;

ALDH1A1 GENE; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER RESISTANCE; CARCINOGENICITY; EPIGENETICS; GENE; GENETIC TRANSCRIPTION; HISTONE METHYLATION; HUMAN; HUMAN TISSUE; IRRADIATION; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; PROSTATE CANCER CELL LINE; RADIOSENSITIZATION; ANIMAL; CHROMATIN IMMUNOPRECIPITATION; COMPARATIVE GENOMIC HYBRIDIZATION; DNA METHYLATION; DNA MICROARRAY; FLOW CYTOMETRY; FLUORESCENCE MICROSCOPY; GENE EXPRESSION REGULATION; GENETIC EPIGENESIS; GENETICS; NUDE MOUSE; PROSTATE TUMOR; RADIATION RESPONSE; RADIATION TOLERANCE; RADIOTHERAPY; TUMOR CELL LINE; WESTERN BLOTTING; XENOGRAFT;

ANIMALS; BLOTTING, WESTERN; CELL LINE, TUMOR; CHROMATIN IMMUNOPRECIPITATION; COMPARATIVE GENOMIC HYBRIDIZATION; DNA METHYLATION; EPIGENESIS, GENETIC; FLOW CYTOMETRY; GENE EXPRESSION REGULATION, NEOPLASTIC; HETEROGRAFTS; HISTONES; HUMANS; MALE; MICE; MICE, NUDE; MICROSCOPY, FLUORESCENCE; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROMOTER REGIONS, GENETIC; PROSTATIC NEOPLASMS; RADIATION TOLERANCE; RADIOTHERAPY; RETINAL DEHYDROGENASE;

EID: 84969645590     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-15-2116     Document Type: Article

References (55)

1. Ferlay J, Steliarova-Foucher E, Lortet-Tieulent J, Rosso S, Coebergh JW, Comber H, et al. Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012. Eur J Cancer 2013;49:1374-403.
2. Ghotra VP, Geldof AA, Danen EH. Targeted radiosensitization in prostate cancer. Curr Pharm Des 2013;19:2819-28.
3. Rukstalis DB. Treatment options after failure of radiation therapy - a review. Rev Urol 2002;4Suppl 2:S12-7.
4. Zietman AL, Bae K, Slater JD, Shipley WU, Efstathiou JA, Coen JJ, et al. Randomized trial comparing conventional-dosewith high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol 2010;28:1106-11.
5. Pahlajani N, Ruth KJ, Buyyounouski MK, Chen DY,Horwitz EM, Hanks GE, et al. Radiotherapy doses of 80 Gy and higher are associated with lower mortality in men with Gleason score 8 to 10 prostate cancer. Int J Radiat Oncol Biol Phys 2012;82:1949-56.
6. Johansson S, Astrom L, Sandin F, Isacsson U, Montelius A, Turesson I. Hypofractionated proton boost combined with external beam radiotherapy for treatment of localized prostate cancer. Prostate Cancer 2012;2012: 654861.
7. Baumann M, Krause M, Hill R. Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer 2008;8:545-54.
8. Brunner TB, Kunz-Schughart LA, Grosse-Gehling P, Baumann M. Cancer stem cells as a predictive factor in radiotherapy. Semin Radiat Oncol 2012;22:151-74.
9. Pajonk F, Vlashi E, McBride WH. Radiation resistance of cancer stem cells: the 4 R's of radiobiology revisited. Stem Cells 2010;28: 639-48.
10. O'Brien CA, Kreso A, Jamieson CH. Cancer stem cells and self-renewal. Clin Cancer Res 2010;16:3113-20.
11. Baumann M, Dubois W, Suit HD. Response of human squamous cell carcinoma xenografts of different sizes to irradiation: relationship of clonogenic cells, cellular radiation sensitivity in vivo, and tumor rescuing units. Radiat Res 1990;123:325-30.
12. Hill RP, Milas L. The proportion of stem cells in murine tumors. Int J Radiat Oncol Biol Phys 1989;16:513-8.
13. Butof R, Dubrovska A, Baumann M. Clinical perspectives of cancer stem cell research in radiation oncology. Radiother Oncol 2013;108: 388-96.
14. Linge A, Löck S, Gudziol V, Nowak A, Lohaus F, von Neubeck C, et al. Low cancer stem cell marker expression and low hypoxia identify good prognosis subgroups in HPV(-) HNSCC after postoperative radiochemotherapy: a multicenter study of the DKTK-ROG. Clin Cancer Res 2016 Jan 11. doi: 10. 1158/1078-0432. CCR-15-1990.
15. Kreso A, Dick JE. Evolution of the cancer stem cell model. Cell Stem Cell 2014;14:275-91.
16. Cojoc M, Peitzsch C, Kurth I, Trautmann F, Kunz-Schughart LA, Telegeev GD, et al. Aldehyde dehydrogenase is regulated by Beta-catenin/TCF and promotes radioresistance in prostate cancer progenitor cells. Cancer Res 2015;75:1482-94.
17. Frame FM, Pellacani D, Collins AT, Simms MS,Mann VM, Jones GD, et al. HDAC inhibitor confers radiosensitivity to prostate stem-like cells. Br J Cancer 2013;109:3023-33.
18. Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C. Clonogenic assay of cells in vitro. Nat Protoc 2006;1:2315-9.
19. van den Hoogen C, van der Horst G, Cheung H, Buijs JT, Lippitt JM, Guzmán-Ramírez N, et al. High aldehyde dehydrogenase activity identifies tumor-initiating and metastasis-initiating cells in human prostate cancer. Cancer Res 2010;70:5163-73.
20. Dubrovska A, Elliott J, Salamone RJ, Kim S, Aimone LJ, Walker JR, et al. Combination therapy targeting both tumor-initiating and differentiated cell populations in prostate carcinoma. Clin Cancer Res 2010;16: 5692-702.
21. McDonald OG, Wu H, Timp W, Doi A, Feinberg AP. Genome-scale epigenetic reprogramming during epithelial-to-mesenchymal transition. Nat Struct Mol Biol 2011;18:867-74.
22. Berezovska OP, Glinskii AB, Yang Z, Li XM, Hoffman RM, Glinsky GV. Essential role for activation of the Polycomb group (PcG) protein chromatin silencing pathway in metastatic prostate cancer. Cell Cycle 2006;5: 1886-901.
23. Sharma A, Singh K, Almasan A. Histone H2AX phosphorylation: a marker for DNA damage. Methods Mol Biol 2012;920:613-26.
24. Menegakis A, von Neubeck C, Yaromina A, Thames H, Hering S, Hennenlotter J, et al. gammaH2AX assay in ex vivo irradiated tumour specimens: a novelmethod to determine tumour radiation sensitivity in patient-derived material. Radiother Oncol 2015;116:473-9.
25. LeMagnen C, Bubendorf L, Rentsch CA, Mengus C, Gsponer J, Zellweger T, et al. Characterization and clinical relevance of ALDHbright populations in prostate cancer. Clin Cancer Res 2013;19:5361-71.
26. Nieto MA. Epithelial plasticity: a common theme in embryonic and cancer cells. Science 2013;342:1234850.
27. de la Roche M, Ibrahim AE, Mieszczanek J, Bienz M. LEF1 and B9L shield beta-catenin from inactivation by Axin, desensitizing colorectal cancer cells to tankyrase inhibitors. Cancer Res 2014;74:1495-505.
28. Deshmukh D,Qiu Y. Role of PARP-1 in prostate cancer. AmJ Clin ExpUrol 2015;3:1-12.
29. Baumann M, Krause M, Overgaard J, Debus J, Bentzen SM, Daartz J, et al. Radiation oncology in the era of precision medicine. Nat Rev Cancer 2016;16:234-49.
30. KuhlmannJD,Hein L, Kurth I, Wimberger P, Dubrovska A. Targeting cancer stem cells: promises and challenges. Anticancer Agents Med Chem 2015; 16:38-58.
31. Peitzsch C, Kurth I, Kunz-Schughart L, Baumann M, Dubrovska A. Discovery of the cancer stem cell related determinants of radioresistance. Radiother Oncol 2013;108:378-87.
32. Mullighan CG, Phillips LA, Su X, Ma J, Miller CB, Shurtleff SA, et al. Genomic analysis of the clonal origins of relapsed acute lymphoblastic leukemia. Science 2008;322:1377-80.
33. Ding L, Ley TJ, Larson DE, Miller CA, Koboldt DC, Welch JS, et al. Clonal evolution in relapsed acute myeloid leukaemia revealed by whole-genome sequencing. Nature 2012;481:506-10.
34. Stass S, Mirro J, Melvin S, Pui CH, Murphy SB,WilliamsD. Lineage switch in acute leukemia. Blood 1984;64:701-6.
35. Craveiro V, Yang-Hartwich Y, Holmberg JC, Sumi NJ, Pizzonia J, Griffin B, et al. Phenotypic modifications in ovarian cancer stem cells following Paclitaxel treatment. Cancer Med 2013;2:751-62.
36. Meacham CE, Morrison SJ. Tumour heterogeneity and cancer cell plasticity. Nature 2013;501:328-37.
37. Tang DG. Understanding cancer stem cell heterogeneity and plasticity. Cell Res 2012;22:457-72.
38. Peitzsch C, Perrin R, Hill RP, Dubrovska A, Kurth I. Hypoxia as a biomarker for radioresistant cancer stem cells. Int J Radiat Biol 2014;90:636-52.
39. Lagadec C, Vlashi E, Della Donna L, Dekmezian C, Pajonk F. Radiationinduced reprogramming of breast cancer cells. Stem Cells 2012;30: 833-44.
40. Wang Y, Li W, Patel SS, Cong J, Zhang N, Sabbatino F, et al. Blocking the formation of radiation-induced breast cancer stem cells. Oncotarget 2014;5:3743-55.
41. Ghisolfi L, Keates AC, Hu X, Lee DK, Li CJ. Ionizing radiation induces stemness in cancer cells. PLoS One 2012;7:e43628.
42. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, et al. Global histone modification patterns predict risk of prostate cancer recurrence. Nature 2005;435:1262-6.
43. Yang YA, Yu J. EZH2, an epigenetic driver of prostate cancer. Protein Cell 2013;4:331-41.
44. Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K. EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 2003;22:5323-35.
45. Visser HP, Gunster MJ, Kluin-Nelemans HC, Manders EM, Raaphorst FM, Meijer CJ, et al. The Polycomb group protein EZH2 is upregulated in proliferating, cultured humanmantle cell lymphoma. Br J Haematol 2001; 112:950-8.
46. Varambally S, Dhanasekaran SM, Zhou M, Barrette TR, Kumar-Sinha C, Sanda MG, et al. The polycomb group protein EZH2 is involved in progression of prostate cancer. Nature 2002;419:624-9.
47. Jung HY, Jun S, Lee M, Kim HC, Wang X, Ji H, et al. PAF and EZH2 induce Wnt/beta-catenin signaling hyperactivation. Mol Cell 2013;52: 193-205.
48. Taylor BS, Schultz N, Hieronymus H, Gopalan A, Xiao Y, Carver BS, et al. Integrative genomic profiling of human prostate cancer. Cancer Cell 2010;18:11-22.
49. He S, Wang J, Kato K, Xie F, Varambally S, Mineishi S, et al. Inhibition of histone methylation arrests ongoing graft-versus-host disease in mice by selectively inducing apoptosis of alloreactive effector T cells. Blood 2012; 119:1274-82.
50. Liu Z, Ren G, Shangguan C, Guo L, Dong Z, Li Y, et al. ATRA inhibits the proliferation of DU145 prostate cancer cells through reducing the methylation level of HOXB13 gene. PLoS One 2012;7:e40943.
51. Hoffmann MJ, Engers R, Florl AR, Otte AP, Muller M, Schulz WA. Expression changes in EZH2, but not in BMI-1, SIRT1, DNMT1 or DNMT3B are associated with DNA methylation changes in prostate cancer. Cancer Biol Ther 2007;6:1403-12.
52. Saramaki OR, Tammela TL, Martikainen PM, Vessella RL, Visakorpi T. The gene for polycomb group protein enhancer of zeste homolog 2 (EZH2) is amplified in late-stage prostate cancer. Genes Chromosomes Cancer 2006;45:639-45.
53. He LR, Liu MZ, Li BK, Jia WH, Zhang Y, Liao YJ, et al. High expression of EZH2 is associated with tumor aggressiveness and poor prognosis in patients with esophageal squamous cell carcinoma treated with definitive chemoradiotherapy. Int J Cancer 2010;127:138-47.
54. Meng X, Huang Z, Wang R, Jiao Y, Li H, Xu X, et al. The prognostic role of EZH2 expression in rectal cancer patients treated with neoadjuvant chemoradiotherapy. Radiat Oncol 2014;9:188.
55. Kim SH, Joshi K, Ezhilarasan R, Myers TR, Siu J, Gu C, et al. EZH2 protects glioma stem cells from radiation-induced cell death in a MELK/FOXM1-dependent manner. Stem Cell Rep 2015;4:226-38.